Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (43) clinical trials

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma. This study includes 2 parts, Phase 1 dose escalation and Phase 1 dose expansion. …


Pembrolizumab in Treating Younger Patients With Recurrent Progressive or Refractory High-Grade Gliomas Diffuse Intrinsic Pontine Gliomas Hypermutated Brain Tumors Ependymoma or Medulloblastoma

PRIMARY OBJECTIVES: I. To establish the safety and describe adverse effects associated with administration of the adult recommended dose of pembrolizumab (MK-3475) in each stratum separately. II. To estimate the sustained objective response rate, (complete response [CR] + partial response [PR], sustained for at least 9 weeks) associated with pembrolizumab …


Hyperpolarized Imaging in Diagnosing Participants With Glioma

PRIMARY OBJECTIVES: To assess the safety and feasibility of hyperpolarized 13C MR metabolic imaging as a new and unique tool for evaluating tumor burden and detecting early response to standard therapy in patients with glioma. To define the most appropriate imaging parameters for obtaining hyperpolarized 13C data from the brain, …


Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months). The median overall survival for GBM patients is 12-14 months from the time of diagnosis; therefore the development …


Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

PRIMARY OBJECTIVES: I. To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab and placebo, ipilimumab and placebo, and nivolumab and ipilimumab in children and young adults with recurrent or progressive high grade glioma (HGG) when compared to a cohort of …


Nedisertib and Radiation Therapy Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of nedisertib (M3814) in combination with standard of care radiation dose (60 Gy, 2 Gy/fraction over 6 weeks) in patients with newly diagnosed MGMT unmethylated glioblastoma (GBM). (Stage I) II. To determine the ability of M3814 to cross the blood …


Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Background Although the survival of gliomas has improved, most high grade gliomas will recur in field or adjacent to the treatment field within months to years of the original treatment. In newly diagnosed GBM, the concurrent use of radiation and temozolomide is standard of care. Surgical resection upon recurrence is …


Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. But in most patients with advanced cancer, T-cells are not stimulated enough …


Phase I Study of APX005M in Pediatric CNS Tumors

This is a multicenter phase I trial of APX005M in patients with recurrent or refractory primary malignant central nervous system tumor, or newly diagnosed diffuse intrinsic pontine glioma. APX005M is a humanized IgG1 mAb that binds to CD40. APX005M binds to both human and cynomolgus monkey CD40 with high affinity, …


Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Participants will be stratified by the biological characteristics of their tumor to one of two treatment strata: STRATUM A Combination Treatment: prexasertib and cyclophosphamide Patient population: Participants with recurrent/refractory Group 3 and Group 4 (G3/G4) medulloblastoma, recurrent/refractory sonic hedgehog (SHH) medulloblastoma and medulloblastoma participants with Indeterminate molecular subgroup STRATUM B …